imfinzi
astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
microtrast 70 % oral pasta
guerbet - bariumsulfat - oral pasta - 70 %
thiram exportbejdse flydende bejdse
arysta lifescience great britain ltd. - thiram - flydende bejdse - 480 g/l thiram
kobberoxychlorid 51% cu pulver
forhandles af flere firmaer. - kobberoxychlorid, kobber - pulver - 844,3 g/kg kobberoxychlorid ; (~ 510 g/kg kobber)
contalgin 30 mg depotgranulat til oral suspension, enkeltdosisbeholder
pfizer aps - morphinsulfat - depotgranulat til oral suspension, enkeltdosisbeholder - 30 mg
contalgin 60 mg depotgranulat til oral suspension, enkeltdosisbeholder
pfizer aps - morphinsulfat - depotgranulat til oral suspension, enkeltdosisbeholder - 60 mg
omeprazol "matrix pharmaceuticals" 20 mg enterokapsler, hårde
matrix pharmaceuticals a/s - omeprazol - enterokapsler, hårde - 20 mg
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - humant igg1 monoklonalt antistof specifikt for human interleukin-1 alfa - kolorektale neoplasmer - antineoplastiske midler - behandling af metastatisk kolorektal cancer.
remix flydende middel
adama northern europe b.v. - uspecificeret - flydende middel - 0 g/l uspecificeret
kinetic flydende middel
basf a/s - uspecificeret - flydende middel - 0 g/l uspecificeret